199 results on '"Traina, Fabíola"'
Search Results
2. Autophagy as a Limiting Factor to the Effectiveness of Tyrosine Kinase Inhibitors in Blood Cancers
3. An updated outlook on autophagy mechanism and how it supports acute myeloid leukemia maintenance
4. Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia
5. Microcosting analysis of haematopoietic stem cell transplantation and chemotherapy with intermediate doses of cytarabine in the treatment of acute myeloid leukaemia
6. NT157 exhibits antineoplastic effects by targeting IRS and STAT3/5 signaling in multiple myeloma
7. Antineoplastic effects of pharmacological inhibitors of aurora kinases in CSF3RT618I-driven cells
8. Telomeric repeat-containing RNA is dysregulated in acute myeloid leukemia
9. Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel
10. New germline GATA1 variant in females with anemia and thrombocytopenia
11. Telomere dynamics and hematopoietic differentiation of human DKC1-mutant induced pluripotent stem cells
12. PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia
13. Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation
14. Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis
15. Hypercoagulability and Sickle Cell Disease
16. Paclitaxel induces Stathmin 1 phosphorylation, microtubule stability and apoptosis in acute lymphoblastic leukemia cells
17. NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia
18. ARHGAP6 transcript levels are associated with molecular risk and impact survival outcomes in acute myeloid leukemia
19. Imbalanced receptors, gene signatures, and function of NK subsets predicts poor clinical outcomes in AML
20. Reversine triggers mitotic catastrophe and apoptosis in K562 cells
21. Differential profile of PIP4K2A expression in hematological malignancies
22. Pyrimidine-5′-nucleotidase Campinas, a new mutation (p.R56G) in the NT5C3 gene associated with pyrimidine-5′-nucleotidase type I deficiency and influence of Gilbert's Syndrome on clinical expression
23. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412
24. Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells
25. International Expansion of Modern AML Therapy
26. Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells
27. MDR-1 and GST polymorphisms are involved in myelodysplasia progression
28. IL10 inversely correlates with the percentage of CD8+ cells in MDS patients
29. PTK2 and PTPN11 expression in myelodysplastic syndromes
30. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes
31. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A
32. Effects of thalidomide on long-term bone marrow cultures from patients with myelodysplastic syndromes: Induction of IL-10 expression in the stromal layers
33. Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes
34. Low bone mass density is associated with hemolysis in brazilian patients with sickle cell disease
35. Rho Kinase Regulates the Survival and Transformation of Cells Bearing Oncogenic Forms of KIT, FLT3, and BCR-ABL
36. Microcosting Analysis of Hematopoietic Stem Cell Transplantation and Chemotherapy with Intermediate Doses of Cytarabine in the Treatment of Acute Myeloid Leukemia
37. External Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI): Strong Calibration in the Brazilian Prospective Hodgkin Lymphoma Registry
38. Autophagy Induction Constitutes a Targetable Vulnerability in FLT3-Mutant Acute Myeloid Leukemia Cells Treated with FLT3-Inhibitors
39. Real-World Data for FLT3-Mutated Acute Myeloid Leukemia Patients Treated in Resource-Constrained Settings
40. Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study
41. Erratum on “Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation”
42. ABSENT CD33 IN AML PATIENTS: FROM DIAGNOSIS TO FOLLOW-UPS
43. High MN1 Expression Is Associated with an Lspc-Enriched Phenotype and Glycolysis Representing a New Vulnerability in Acute Myeloid Leukemia
44. Metformin Inhibits STAT3 and MAPK Signaling through AMPK Activation in CSF3RT618I Cells
45. Dysregulated Activating and Inhibitory Receptors on Natural Killer Cells Predicts Immune Escape and Poor Outcomes in Acute Myeloid Leukemia
46. IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes
47. Co‐occurrence of BCR–ABL1‐positive chronic myeloid leukaemia and CALR‐mutated essential thrombocythaemia
48. Stathmin 1 expression in plasma cell neoplasms
49. Differential profile of CDKN1A and TP53 expressions in bone marrow mesenchymal stromal cells from myeloid neoplasms
50. Clinical features of JAK2V617F- or CALR-mutated essential thrombocythemia and primary myelofibrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.